Parabilis prices upsized U.S. IPO

Parabilis Medicines Inc., a clinical-stage cancer drug developer based in Cambridge, Massachusetts, has completed the pricing of an upsized U.S. initial public offering. The company sold 33.5 million shares of common stock at an IPO price of $20 per share, generating approximately $670 million in gross proceeds before underwriting discounts and offering expenses. The IPO priced above a previously marketed range and reflected an increase in deal size relative to earlier plans.

Parabilis is expected to begin trading on the Nasdaq Global Select Market under the ticker symbol "PBLS" on June 10, 2026. The offering is anticipated to close on or about June 11, 2026, subject to customary closing conditions. These milestones mark Parabilis’s transition to the public equity markets as it continues development of its cancer drug pipeline.

In conjunction with the IPO, Parabilis entered into a concurrent private placement agreement with Regeneron Pharmaceuticals (REGN). Under this agreement, Parabilis will sell 4,166,666 shares of common stock to Regeneron at a price of $18.00 per share, representing 90% of the IPO price. The private placement is expected to generate roughly $75 million in additional proceeds for the company.

The closing of the private placement is conditioned on the closing of the IPO. Taken together, the IPO and the private placement result in total capital raised of nearly $745 million. This combined financing substantially increases the company’s available resources following its market debut.

Parabilis assembled a broad underwriting syndicate for the IPO. Leerink Partners, BofA Securities, Evercore ISI and Guggenheim Securities are acting as joint book-running managers for the offering. LifeSci Capital is participating as a passive bookrunning manager. This group is responsible for placing shares with institutional and other investors and supporting initial trading in the stock.

The company granted the underwriters a 30-day option to purchase up to an additional 5,025,000 shares of common stock at the IPO price, less underwriting discounts and commissions. If exercised, this overallotment option would further increase the total number of shares sold and the proceeds raised, although the exact impact depends on whether and to what extent the option is used.

Prior to final pricing, Parabilis had marketed the upsized offering at 33.3 million shares in a price range of $17 to $19 per share. At those terms, the company was targeting a valuation of up to nearly $2.3 billion. The final IPO terms reflect both a modest increase in share count versus the marketed amount and a per-share price set above the indicated range.

The move from the marketing range to a final price of $20 per share, together with the concurrent private placement, resulted in higher gross proceeds than the marketed scenario. The upsized and above-range pricing indicates that investor demand supported more capital and a higher per-share level than originally signaled during the marketing phase.